Immutep's clinical trial utilized MSD's anti-PD-1 drug, and the FDA provided positive feedback regarding the potential for treatment development.
2 reports, 2 independent
Updated Aug 17
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Immutep's clinical trial utilized MSD's anti-PD-1 drug, and the FDA provided positive feedback regarding the potential for treatment development.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Immutep reports activities from Sydney, Australia.Sub-event
FDA acknowledged potential for treatment development based on Immutep's trial using MSD's anti-PD-1 drug.1 source
Immutep's clinical data, combining efti with Merck's KEYTRUDA, received positive FDA feedback.1 source
Keep exploring
The entities involved
Coverage
Newest first; wire copies grouped- Insider MonkeyImmutep Limited (IMMP) Receives Positive FDA Feedback on Future Clinical Development of Eftilagimod Alfa Immutep Limited (NASDAQ:IMMP) is among the 12 Best Australian Stocks to Buy Right Now. On Augu
- GlobeNewswireImmutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1 SYDNEY, AUSTRALIA, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Immutep Lim